1www.ResearchToPractice.com/RTPTV2011

Select Publications

Bang Y et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the Phase III CLASSIC trial. Proc ASCO 2011;Abstract LBA4002.

Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GE junction cancer (ToGA): A Phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97. Abstract

Barok M et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011;306(2):171-9. Abstract

Fuchs CS et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. Proc ASCO 2011;Abstract 4003.

GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer — A meta-analysis. JAMA 2010;303(17):1729-37. Abstract

Park SH et al. A multicenter, randomized Phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). Proc ASCO 2011;Abstract 4004.

Phillips BE et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarci-nomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). Proc ASCO 2011;Abstract 4046.

Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3(1):76-99. Abstract

Shah MA et al. Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 2011;17(9):2693-701. Abstract

Shah MA et al. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A US and European international collaborative analysis. Proc ASCO 2011;Abstract 4014.

Spratlin JL et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7. Abstract

Yoon HH et al. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). Proc ASCO 2011;Abstract 4012.

G A S T R I C C A N C E R

2www.ResearchToPractice.com/RTPTV2011

A study of bevacizumab in combination with capecitabine and cisplatin as first-line therapy in patients with advanced gastric cancer (AVAGAST). NCT00548548.

Clinical practice surveillance of the use of Herceptin in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) (HERMES). NCT01220934.

Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: A random-ized Phase II trial. NCT01123473.

Lapatinib versus lapatinib with capecitabine as second-line treatment in HER2-overexpressing metastatic gastro-esophageal cancer: A randomized Phase II trial. NCT01145404.

Phase II trial of CAPOX, bevacizumab and trastuzumab for patients with HER2-positive metastatic esophagogastric cancer. NCT01191697.

Radiation therapy, paclitaxel, and carboplatin with or without trastuzumab in treating patients with esophageal cancer. NCT01196390.

REAL 3 version 2.0: Trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer. NCT00824785.

Safety and efficacy of RAD001 (everolimus) monotherapy plus best supportive care in patients with advanced gastric cancer (AGC) (GRANITE-1). NCT00879333.